– USA, CA – Paracrine, Inc., a company developing its novel cell therapy platform in late-stage clinical trials in advanced wound care, today announced the appointment of Dr. David Crean (Ph.D.) to its Board as an Independent Director.
“We are delighted to welcome Dr. Crean to the Paracrine Board. David’s board and advisory experiences in the healthcare and biotechnology fields will provide immense value to Paracrine as we continue to execute our strategy of developing safe, cost-effective cell therapies in the $21 billion wound care market,” said Chairman and CEO, Christopher Calhoun.
About David H. Crean
David Crean is Founder and Managing Partner of Cardiff Advisory LLC, an investment banking firm focused on providing strategic and financial advisory for M&A, partnering, and capital financing transactions within the life sciences and healthcare sectors. David is also a Co-Founder and Managing General Partner of Equitos Venture Partners, a life sciences-focused investment firm to start deploying capital in 2022. In addition, David is an investment partner with Suncoast Venture Partners and Mesa Verde Venture Partners, two micro life science seed stage & incubator venture funds.
Dr. Crean currently serves as Chairman of the Board of Directors for Phoenix Molecular Designs, Lead Independent Director of Histogen, Inc. (Nasdaq: HSTO), and serves on the Board of Directors of California Life Sciences (Executive Committee), and BIOCOM (Chairman of Capital Development).
David Crean is a contributing writer for PharmaBoardroom.com and Forbes.com. As a result of his trusted and outstanding advisory work, he has been awarded numerous recognitions including San Diego’s 500 Most Influential people in 2019 – 2021, 2020 Top Thought Leaders by Axial, M&A Advisor of the Year in 2019, and the 2018 Healthcare Hero Award.
“I am happy to join Paracrine’s Board of Directors at this exciting time in the company’s development,” said Dr. David Crean. “Together with the team, I am looking forward to contributing to Paracrine’s clinical and commercialization strategy, achieving the company’s financing goals, and successfully implementing our vision of providing urgently needed innovative therapeutic options in chronic wound care. I am particularly excited with our lead program in treating diabetic foot ulcers, where prior studies have demonstrated Paracrine’s cell therapy resulted in twice the wound closure rate of non-healing ulcers in half the time.”
David Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Investment Banking Representative of BA Securities LLC, Member FINRA SIPC. He holds a Doctorate of Philosophy (Ph.D.) Degree in Biophysics and a Masters of Science (MS) Degree in Oncology from the State University of New York at Buffalo. He earned a Bachelor of Science (BS) Degree in Biology/ Pre-Med from Canisius College. Additionally, he holds a Masters of Business Administration (MBA) Degree with a finance concentration from Pepperdine University Graziadio School of Management.
About Paracrine
Paracrine, Inc. is a biotechnology company committed to unlocking the potential of autologous stem cells for patients suffering from serious chronic illnesses by discovering, developing, and delivering innovative and effective human therapeutics. The company is advancing multiple late-stage clinical trials, initially targeting the $21 billion advanced wound care market segment. Paracrine’s device-enabled cell therapy platform bears the promise of cost-effectively addressing the common underlying pathology of debilitating chronic diseases due to its multi-modal mechanisms of action.
For more information: https://paracrine.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
